Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;50(10):1086-1093.
doi: 10.1111/apt.15511. Epub 2019 Oct 17.

Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort

Affiliations

Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort

Adam Rahman et al. Aliment Pharmacol Ther. 2019 Nov.

Abstract

Background: Lifetime risk of surgery in patients with Crohn's disease remains high.

Aim: To assess population-level markers of Crohn's disease (CD) in the era of biological therapy.

Methods: Population-based cohort study using administrative data from Ontario, Canada including 45 235 prevalent patients in the Ontario Crohn's and Colitis Cohort (OCCC) from 1 April 2003 to 31 March 2014.

Results: CD-related hospitalisations declined 32.4% from 2003 to 2014 from 154/1000 (95% confidence interval (CI) [150, 159]) patients to 104/1000 (95% CI [101, 107]) (P < .001). There was a 39.6% decline in in-patient surgeries from 53/1000 (95% CI [50, 55]) to 32/1000 (95% CI [30, 34]) from 2003 to 2014 (P < .001). In-patient surgeries were mostly bowel resections. Out-patient surgeries increased from 8/1000 (95% CI [7, 9]) patients to 12/1000 (95% CI [10, 13]) (P < .001). Out-patient surgeries were largely related to fistulas and perianal disease and for stricture dilations/stricturoplasty. CD-related emergency department (ED) visits declined 28.4% from 141/1000 (95% CI [137, 146]) cases to 101/1000 (95% CI [99, 104]) from 2003 to 2014 (P < .001). Over the same time, patients receiving government drug benefits received infliximab or adalimumab at a combined rate of 2.2% in 2003 which increased to 18.8% of eligible patients by 2014.

Conclusions: Rates of hospitalisations, ED visits and in-patient surgeries markedly declined in Ontario over the study period, while rates of biologic medication use increased markedly for those receiving public drug benefits.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Rahman A, Williams P, Sandhu A, Mosli M. Malnutrition universal screening tool (MUST) scores predicts disease activity in patients with Crohn's disease. Can J Nutr. 2016;1:1-5.
    1. Sandhu A, Mosli M, Yan B, et al. Self-screening for malnutrition risk in outpatient inflammatory bowel disease patients using the malnutrition universal screening tool (MUST). J Parenter Enteral Nutr. 2016;40:507-510.
    1. Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007;42:602-610.
    1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794.
    1. Peyrin-Biroulet L, Loftus E, Colombel J, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297.

Publication types

MeSH terms

LinkOut - more resources